NCT04749485Unknown2 期
A Single-armed Open-labeled Phase II Study of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments.
Taizhou Hanzhong biomedical co. LTD11 个研究点 分布在 1 个国家目标入组 119 人开始时间: 2018年11月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 119
- 试验地点
- 11
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the efficacy and safety of HX008 in patients with locally advanced or metastatic melanoma who have failed the standard treatments will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent voluntarily. Understand this protocol and be willing and able to adhere to the study visit schedule;
- •Male and Female aged 18 to 75 are eligible;
- •Histologic diagnosis of locally advanced unable to undergo complete resection or metastatic melanoma, while ocular melanoma is excluded, and the overall rate of mucosal melanoma is no more than 22%.
- •Has failed at least 1 prior routine regimen for advanced disease, including chemotherapy, target therapy, immunotherapy, biological therapy (IFN-gamma, interleukin, onco-vaccine, cytokine, oncolytic virus or cancer growth factor inhibition), and the interval between last previous treatment and the first dose of this trial should be ≥ 4 weeks or 5 half-life of the previously administrated drug, which happens first.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Life expectancy ≥ 3 months.
- •At least 1 measurable extracranial lesion based on RECIST v1.1, and no prior radiation to measurable lesions;
- •Central nervous system metastases must be asymptomatic with or without treatment, and be stable for at least 3 months based on CT/MRI, and no need for systemic steroids within 4 weeks prior to the first dose of the study drug.
- •Providing with tumor specimen (for testing the expression of PD -L1);
- •Has sufficient organ and bone marrow function to meet the following laboratory examination standards: neutrophils ≥ 1.5 x 10^9/L; white blood cells ≥3.0 x 10^9/L; platelets ≥ 100 x 10^9/L; hemoglobin ≥ 90 g/L; serum creatinine ≤1x ULN; aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; total bilirubin ≤ 1.5 x ULN; INR≤2 x ULN, aPTT≤1.5 x ULN (except for those undergoing anticoagulant therapy);
- •Reproductive men and women of childbearing age are willing to take effective contraceptive measures from signing the informed consent form to 3 months after the last administration of the trial drug.
排除标准
- •Prior malignancy active within the previous 5 years except for locally curable cancers that have been apparently cured, such as carcinoma in situ of the cervix or basal cell skin cancer.
- •With adverse reactions of previous treatment that have not recovered to CTCAE V5.0 grade ≤ 1, except for the residual hair loss effect.
- •Prior treatment with anti-PD-1/PD-L1/CTLA-4 antibody.
- •With active or history of autoimmune diseases that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulitis, etc.), or patients with high risk (e.g., organ transplantation requiring immunosuppressive therapy). While those with the following diseases were allowed to be enrolled: a) Stable patients with type I diabetes after a fixed dose of insulin; b) Autoimmune hypothyroidism requiring hormone replacement therapy only; c) Skin diseases requiring no systemic treatment (e.g. eczema, skin rash covering less than 10% of the body surface, psoriasis without ophthalmic symptoms, etc.).
- •Expecting to receive major surgery during the study period including 4 weeks prior to the first dose of the study drug.
- •Need to receive systemic corticosteroids (dose equivalent to > 10 mg prednisone / day) or other immunosuppressive drugs within 14 days before enrollment or during the study period. Those under the following conditions are eligible: a) Locally external use or inhaled corticosteroids; b) short-term (≤ 7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases.
- •History of human immunodeficiency virus infection, acquired or congenital immunodeficiency disease, organ transplantation or stem cell transplantation.
- •Has active chronic HBV or HCV infection, except those with HBV DNA viral load ≤500 IU/mL or <10^3 copies/mL, or HCV RNA negative after adequate treatment.
- •Has severe infection within 4 weeks or active infection requiring IV infusion or oral administration of antibiotics within 2 weeks prior to the first dose of the study drug.
- •Known to be allergic to macromolecular protein agents or monoclonal antibody; Known to has a history of severe allergies to any of the components in the study drug (CTCAE v5.0 ≥ grade 3);
- •Has participated in other clinical trial within 4 weeks prior to the first dose of the study drug.
- •Alcohol dependence or drug abuse within recent one year.
- •Has a history of confirmed neurological or mental disorders, such as epilepsy, dementia; or with poor compliance; or the presence of peripheral neurological disorders.
- •Has brain metastasis with symptoms.
- •Is pregnant or breastfeeding.
- •Other reasons disqualifying the entering of this study based on the evaluation of the investigators.
研究组 & 干预措施
HX008
Experimental
干预措施: HX008 (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: 24 months
Percentage of subjects achieving complete response (CR) and partial response (PR).
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
时间窗: 36 months
次要结局
- Progression-Free Survival (PFS)(24 months)
- Duration of Response (DOR)(24 months)
- Overall survival (OS)(36 months)
研究者
研究点 (11)
Loading locations...
相似试验
Unknown
1 期
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast CancerTriple-negative Breast CancerNCT04750382Taizhou Hanzhong biomedical co. LTD31
Unknown
1 期
A Phase Ib Study of HX008 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT04825392Taizhou Hanzhong biomedical co. LTD30
Unknown
2 期
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic MelanomaMetastatic MelanomaAdvanced MelanomaNCT03013101Shanghai Junshi Bioscience Co., Ltd.128
Unknown
2 期
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial CarcinomaBladder Urothelial CarcinomaNCT03113266Shanghai Junshi Bioscience Co., Ltd.370
已完成
2 期
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract CancerBiliary Tract NeoplasmsNCT05190575Shanghai Zhongshan Hospital8